FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

washington, D.C. 20549	

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	e burden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Behbahani Ali				2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX ]																	
(Last) (First) (Middle) 2855 SAND HILL RD					3. Date of Earliest Transaction (Month/Day/Year) 09/20/2024									Officer (give title Other (specify below) below)							
(Street) MENLO (City)	PARK CA		4025 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line)	1 <u>~</u>						
		Table	I - No	n-Deriva	tive S	Secur	ities	Acq	uired,	, Dis	posed of	, or E	ene	ficially	y Own	ed					
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day			Execution Date,		Date,	3. Transaction Code (Instr. 8)  4. Securities Acquired (ADISPOSE OF (D) (Instr. 3D)  5)					ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)							
							Code	v	Amount	(A) (D)	Pr F	Price	Transaction(s) (Instr. 3 and 4)				(111501. 4)				
Common Stock 09/20/			09/20/2	2024				<b>A</b> <sup>(1)</sup>		3,007	A	9	<b>5</b> 4.78 <sup>(2)</sup>	5	7,584		D				
Common Stock														4,4	48,757			See Note 3 <sup>(3)</sup>			
		Tal	ble II -								osed of, convertib				Owne	d					
Security or E (Instr. 3) Price Deri	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	n Date, Transa Code (I				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		De Se (In	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirec Beneficial Ownershi (Instr. 4)		
				,	Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amo or Num of Shar	ber							

## **Explanation of Responses:**

- 1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
- 2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024.
- 3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

/s/ Zachary Bambach, attorney-in-fact

09/20/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.